Page 8 - Bharat Biotech
A big boost
Covaxin gets the stamp of international legitimacy
 "A big boost")
Top headlines: WHO clears Covaxin; Cairn cements end of tax dispute
Business Standard brings you the top headlines on Wednesday
 "Top headlines: WHO clears Covaxin; Cairn cements end of tax dispute")
'WHO's EUL status to Covaxin to accelerate equitable access of vaccine'
In a tweet, the WHO said it has granted emergency use listing (EUL) to Covaxin
 "'WHO's EUL status to Covaxin to accelerate equitable access of vaccine'")
WHO grants much-awaited emergency use listing to Bharat Biotech's Covaxin
Move will ease international travel for those vaccinated with the jab
 "WHO grants much-awaited emergency use listing to Bharat Biotech's Covaxin")
Australia okays Bharat Biotech's Covaxin for travel ahead of WHO meet
The backing of Australia could tip the scale in favour of Covaxin when the WHO meets on November 3
 "Australia okays Bharat Biotech's Covaxin for travel ahead of WHO meet")
Bharat Biotech's Covaxin recognised by Australia for travelers
Hyderabad-based Bharat Biotech's Covaxin, and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India
 "Bharat Biotech's Covaxin recognised by Australia for travelers")
We trust India, Bharat Bio submitting data on EUL of Covaxin regularly: WHO
WHO official says the organisation is in touch with Bharat Biotech and has 'daily conversations' 'clarifying what additional data needs' to be submitted
Covaxin finds place in Oman's list of approved Covid-19 vaccines
Bharat Biotech tweeted, "Covaxin has now been added to the approved list of Covid-19 vaccines for travel to Oman without quarantine. This will facilitate travelers from India vaccinated with Covaxin."
WHO says likely to receive clarifications on Covaxin by weekend
WHO said it expects to receive clarifications from Bharat Biotech by the end of this week on its Covaxin -- and will meet on November 3 for a final risk-benefit assessment for Emergency Use Listing
Top Headlines: Paytm ups IPO size to Rs 18,300 cr, no nod for Covaxin yet
Business Standard brings you the top headlines at this hour
 "Top Headlines: Paytm ups IPO size to Rs 18,300 cr, no nod for Covaxin yet")
No nod for Bharat Bio's Covaxin yet, WHO seeks 'additional clarifications'
The technical advisory group will now meet on November 3 for a final assessment.
Review of Covaxin underway, expect a recommendation within 24 hours: WHO
A technical advisory group of the WHO reviewing data on Covaxin for the emergency use listing of India's vaccine and if it is satisfied a recommendation is expected within the next 24 hours or so
Vaccine makers meet WTO D-G, flag excess capacity of Covid-19 jabs
Some manufacturers also said that the regulatory approval framework for Covid-19 vaccines in other nations also takes a substantial amount of time
 "Vaccine makers meet WTO D-G, flag excess capacity of Covid-19 jabs")
WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX
WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating ...
 "WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX")
Top headlines: Govt plans IDBI sale; chief economist Gopinath to leave IMF
India's drug regulator is examining recommendation by experts for approving Bharat Biotech's Covaxin for children. More in top headlines this morning.
Bharat Biotech's Covaxin roll-out for children likely in phases
Vaccine performance, availability being evaluated
 "Bharat Biotech's Covaxin roll-out for children likely in phases")
Long wait: Vaccine makers queue up for WHO approval, shows data
Industry insiders say typically a WHO EUL takes between two months and a year
 "Long wait: Vaccine makers queue up for WHO approval, shows data")
WHO expecting more info from Bharat Biotech for Covaxin approval
Covaxin is one of the three approved vaccines that have been used in India for the country's vaccination drive for adults.
Top headlines: NCLT setback for Amazon; WHO seeks more info for Covaxin
Business Standard brings you the top stories from today
 "Top headlines: NCLT setback for Amazon; WHO seeks more info for Covaxin")
WHO's technical group to meet on Oct 26 to consider EUL of Covaxin
The WHO experts are currently reviewing this information and if it addresses all questions raised, the WHO assessment will be finalised next week